April 22, 2011 – The U.S. Food and Drug Administration (FDA) has cleared the Trifecta valve, by St. Jude Medical. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart. The valve was designed for excellent hemodynamic performance (the optimization of blood flow through the valve) and long-term durability. To ensure the structural integrity of the valve, it is constructed using a polyester and tissue-covered titanium stent, or base. The valve features leaflets manufactured from pericardial tissue attached to the exterior of the valve stent. This design allows the leaflets to open more fully and efficiently, mimicking the performance of a healthy aortic heart valve and limiting tissue abrasion through tissue-to-tissue (stent-to-leaflet) contact. Also contributing to the valve’s durability, it offers the Linx AC Technology, an anticalcification treatment designed to reduce tissue mineralization (hardening), one of the primary causes of valve deterioration. It also offers several features that improve the ease of implantation, including the valve’s unique holder, designed to improve visibility and cuff access for suturing, and customized sizes. “Physicians around the world have already voiced tremendous excitement and satisfaction with the Trifecta valve,” said Frank J. Callaghan, president of the St. Jude Medical cardiovascular division. “Trifecta has demonstrated outstanding hemodynamic performance and has improved the lives of patients with aortic valve disease.” The valve was approved by regulatory authorities in Europe and Canada in 2010. For more information: www.sjm.com
If you enjoy this content, please share it with a colleague
FDA Clears Trifecta Stented Tissue Aortic Valve
Related Content
April 30, 2024 — The expanding use of transcatheter technologies has changed the landscape in the treatment of valvular ...
April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...
March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...
February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...
The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...
January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...
January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...
December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...
December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...
November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...